Medicus Pharma (NASDAQ:MDCX) Issues Earnings Results

Medicus Pharma (NASDAQ:MDCX) announced its quarterly earnings data on Wednesday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports.

Medicus Pharma Stock Down 4.3%

Shares of NASDAQ:MDCX traded down $0.01 on Wednesday, hitting $0.33. 1,099,044 shares of the company traded hands, compared to its average volume of 3,489,210. The stock has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.55. The company has a market cap of $18.76 million, a PE ratio of -0.12 and a beta of 0.12. Medicus Pharma has a 52 week low of $0.25 and a 52 week high of $3.05.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MDCX. Alliance Global Partners initiated coverage on shares of Medicus Pharma in a research note on Tuesday, July 28th. They issued a “buy” rating for the company. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Medicus Pharma in a research note on Monday, April 20th. Roth Capital assumed coverage on shares of Medicus Pharma in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Trading of Medicus Pharma

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Medicus Pharma during the 2nd quarter valued at about $41,000. Osaic Holdings Inc. grew its holdings in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after buying an additional 9,000 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Medicus Pharma during the third quarter valued at approximately $59,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after acquiring an additional 17,611 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.